智通财经APP获悉，兆科眼科-B(06622)盘中涨超7%，截至发稿，涨3.44%，报3.61港元，成交额1143.15万港元。
消息面上，1月26日，兆科眼科宣布，将其核心老花眼治疗药物BRIMOCHOL™ PF在新加坡和越南的独家商业化权利，分别授予新西兰的AFT Pharmaceuticals和日本的千寿制药。至此，兆科眼科其全球化商业版图已延伸至韩国、澳洲、新西兰、泰国、印度尼西亚、台湾地区、新加坡和越南八个市场。
根据协议，兆科眼科授予AFT在新加坡、授予千寿在越南的独家分销权。AFT Pharmaceuticals 是一家总部位于新西兰的跨国制药公司，其商业模式核心在于在全球超过125个国家开发和授权产品。千寿制药则是一家以研发为核心的日本私人制药公司，尤其在眼科领域深耕多年，旨在通过原创药品提升全球患者的视力健康。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.